itstargetnews
Palo Alto Investors LP reported a purchase of 41,303 shares of PTC therapeutics (NASDAQ:PTCT) in its SEC filing on February 17, 2026, with an estimated transaction value of $3.00 million based on quarterly average prices.
According to SEC file dated February 17, 2026 Palo Alto Investors LP increased its position in PTC Therapeutics by 41,303 shares during Q4 2025. The estimated transaction value for the additional shares was $3.00 million, based on quarter’s average closing prices. The fund’s holdings in PTC Therapeutics were valued at $68.66 million at the end of the quarter, up $15.72 million from the previous period, a change that reflects both rising holdings and price appreciation.
Palo Alto Investors LP reported a buy; PTC Therapeutics represents 9.56% of 13F reportable AUM as of December 31, 2025.
Main funds after presentation:
-
NASDAQ:INSM: $85.19M (11.9% of AUM)
-
NASDAQ: FOLD: $74.13M (10.3% of AUM)
-
NASDAQ:PTCT: $68.66M (9.6% of AUM)
-
NASDAQ:ACAD: $66.35M (9.2% of AUM)
-
NASDAQ:BMRN: $44.35M (6.2% of AUM)
As of February 17, 2026, shares of PTC Therapeutics were priced at $69.17, up 39.9% year-to-date, outperforming the S&P 500 by 21.57 percentage points.
|
metric |
value |
|---|---|
|
Revenue (TTM) |
806.78 million dollars |
|
net income (TTM) |
($363.30 million) |
|
Market capitalization |
5.58 billion dollars |
|
Price (as of market close on 2/17/26) |
$69.17 |
-
It offers marketed therapies such as Translarna and Emflaza for Duchenne muscular dystrophy, Tegsedi and Waylivra for rare diseases and Evrysdi for spinal muscular atrophy, with additional candidates in development.
-
It operates a biopharmaceutical model focused on the discovery, development and commercialization of medicines for rare disorders, generating revenue primarily from product sales and strategic partnerships.
-
It serves patients with rare diseases, targeting healthcare providers, hospitals and specialty clinics in North America, Europe, Latin America and select international markets.
PTC Therapeutics, Inc. is a biotechnology company specializing in treatments for rare diseases, leveraging a strong portfolio of commercial products and research candidates. The company’s strategic partnerships and focus on high-need therapeutic areas support its competitive position in the rare disease market. With a global reach and emphasis on innovation, PTC Therapeutics aims to address unmet medical needs and drive long-term growth through continued investment in R&D.
Palo Alto Investors, a California-based investment firm, recently bought 41,000 shares of PTC Therapeutics, a biotech company. Here’s what average investors should know.
